P09.56 Comparison of the effect of different treatment strategies within discrepant health-care systems on survival of glioblastoma patients

OBJECTIVE: Although interdisciplinary, longitudinal treatment of glioblastoma patients is standard-of-care for most countries, its effect on glioblastoma patients survival has not been quantified. The goal of this study was to examine survival in similar cohorts of glioblastoma patients from two uni...

Full description

Saved in:
Bibliographic Details
Published in:Neuro-oncology (Charlottesville, Va.) Va.), 2017-05, Vol.19 (suppl_3), p.iii82-iii83
Main Authors: Stavrinou, P., Kalyvas, A., Katsigiannis, S., Hamisch, C., Krischek, B., Stranjalis, G., Goldbrunner, R.
Format: Article
Language:English
Subjects:
POSTER PRESENTATIONS
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OBJECTIVE: Although interdisciplinary, longitudinal treatment of glioblastoma patients is standard-of-care for most countries, its effect on glioblastoma patients survival has not been quantified. The goal of this study was to examine survival in similar cohorts of glioblastoma patients from two university hospitals with different treatment strategies functioning within two completely different healthcare systems. METHODS: We retrospectively analyzed two matched cohorts from a university hospital in Greece (188 patients) and Germany (189 patients). In both centers patients were treated with surgery followed by radiochemotherapy according to the stupp protocol. In case of recurrence, Greek patients were treated rather conservatively and further therapeutic decisions were made solely by the primary treating physician whereas German patients were treated more aggressively, with an individual strategy that was developed within an interdisciplinary tumorboard. The primary endpoint was progression-free and overall survival. Groups were compared using the Kaplan-Meier method for survival estimates. Results: Both groups were comparable with respect to baseline parameters. Only 17% of Greek patients versus 88% of German patients received second line treatment. Progression-free survival was similar for both patient cohorts (PFS Greece =9,9 months vs PFS Germany =9,0 months, p=0,37). Median survival was 12 months (95% CI, 9,4-14,5) and 16,6 months (95% CI, 13,3-19.8) for Greek and German patients respectively (p=0,02). CONCLUSION: Treatment steered by a neurooncological tumorboard, functioning within a well financed-health care system and favoring second-line treatment for recurrent glioblastomas was associated with significantly better overall survival.
ISSN:1522-8517
1523-5866
DOI:10.1093/neuonc/nox036.311